This change was accompanied by significantly decreased plasma insulin levels (Fig. 2E, 1.51 ± 0.15 ng/ml versus 0.83 ± 0.16 ng/ml for Cre−versus Cre+, p < 0.05), suggesting that the observed hyperglycemia, caused by Pax6 deletion, is likely to be due to insufficient insulin output from pancreatic β cells. Here, PAX6 is linked to Hyperglycemia.